Landscape of somatic DNA damage repair (DDR) gene mutations in genitourinary cancer in China.
Kaiwei Yang, MD

May 28th, 2020 - Background: DDR gene alterations(GAs) are prevalent in cancer and play key roles in tumorigenesis, progression and therapeutic response. However, the molecular profile of DDR in genitourinary cancer is still lacking in Asian. In this study, we assessed DDR GAs for better understanding therapeutic implications. Methods: Patients(pts) diagnosed with genitourinary cancer were enrolled. Tumors and ...

Survival outcomes of metastatic renal cell carcinoma (RCC) patients with pancreatic metastases (PM): Pooled analysis from a large clinical trials database.
Justin Shaya, MD

May 28th, 2020 - Background: Pancreatic metastases are a rare site of metastasis for RCC. It has been suggested that patients with metastases to the pancreas have a more indolent disease course, however long term survival outcomes with systemic therapy are not well defined. Methods: We conducted a pooled analysis of metastatic RCC patients treated in phase II/III clinical trials. The primary objective was to ev...

Minimally invasive partial nephrectomy versus percutaneous cryoablation for stage Ia renal cell carcinoma: A cost-effectiveness analysis.
Xiao Wu

May 28th, 2020 - Background: Minimally invasive partial nephrectomy (PN) and percutaneous cryoablation (Cryo) are treatment strategies for renal cell carcinoma (RCC). The purpose of this study is to assess the cost-effectiveness of PN and Cryo for stage Ia RCC. Methods: A decision-analysis model was constructed over 5 years from a health care sector’s perspective using TreeAge Pro Suite 2019 (TreeAge Software L...

Response to checkpoint inhibitors (CPI) in sarcomatoid renal cell carcinoma (sRCC).
Iris Yeong- Fung Sheng, MD

May 28th, 2020 - Background: sRCC have a generally poor prognosis though recent clinical trial data suggest improved outcomes with CPI. We present a real-world experience of metastatic sRCC patients (pts) treated with a variety of CPI. Methods: Pts with sRCC treated with CPI Cleveland Clinic from 1/1/2015 to 12/31/2019 were identified. Overall survival (OS) was estimated using Kaplan-Meier and compared by log r...

Multistate Markov modelling of long-term outcomes in immunotherapy for metastatic renal cell carcinoma (mRCC) using machine-learned dynamic Bayesian networks.
Alind Gupta

May 28th, 2020 - Background: Patient-level heterogeneity in response to treatment remains a major challenge in cancer immunotherapy. Long-term individual-level modelling of survival, tumour response and safety outcomes jointly can help improve efficacy and durable clinical benefits. Machine-learned Bayesian networks provide a solution to the “black box” problem of other machine-learning approaches. Objectives: ...

Receptor tyrosine kinases and growth factors expression in tumor thrombus cells in patients with renal cell carcinoma (RCC).
Maria Volkova

May 28th, 2020 - Background: To our knowledge, this is a first study describing the expression of the receptor tyrosine kinases (RTKs) and growth factors (GFs) in venous tumor thrombus cells and comparing results with the expression in primary RCC. Methods: Formalin-fixed paraffin-embedded specimens of tumor thrombus and primary tumor removed from 25 untreated pT3a-T4N0-1M0-1 RCC patients were evaluated by immu...

Underrepresentation of genitourinary cancers in studies of venous thromboembolism (VTE) prophylaxis.
Max S Perlmutt, BA

May 28th, 2020 - Background: Significant advances in the management of VTE in cancer have led to a recent ASCO clinical practice update for VTE prophylaxis and treatment in patients with cancer. Genitourinary (GU) cancers (including bladder, kidney, prostate, testicular) have a high incidence of VTE, but also frequent bleeding complications, and it is not clear if patients with GU cancers are adequately represe...

Examining the real-world utility of immune checkpoint inhibitors in genitourinary oncology: A single-institution retrospective.
Lydia Glick, BS, BA

May 28th, 2020 - Background: Immune Checkpoint Inhibitors (ICI) are increasingly utilized for genitourinary (GU) malignancies. However, data is lacking on the efficacy of these drugs in “real-world” populations - patients who do not fit the strict clinical trial criteria, but may still benefit from therapy. We performed a retrospective analysis of patients receiving ICI at a single tertiary-care institution, wi...

Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 ...
Sara Elena Rebuzzi

May 28th, 2020 - Background: Biomarkers to select mRCC patients most likely to benefit to immunotherapy are needed. The retrospective multicentre Meet-URO-15 study evaluated the prognostic role of peripheral blood cells in mRCC patients treated with Nivolumab. Methods: Complete blood count was assessed at the first four cycles of Nivolumab. The primary endpoint was median overall survival (mOS) according to bNL...

First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort.
Whitley Hatton

May 28th, 2020 - Background: Combination regimens containing a programmed cell death protein 1 (PD-1) or a programmed cell death ligand 1 (PD-L1) inhibitor improve the clinical outcomes of previously untreated aRCC. These regimens are clinically active but are associated with adverse events (AEs). One prospective study (KEYNOTE-427) has shown clinical activity of pembrolizumab monotherapy in aRCC. We aimed to d...

Profiling antigen specificity concurrently with protein and mRNA quantification using high throughput single-cell multiomics reveal surprising similarities between bystander and tumor specific CD8...
Aaron Tyznik

May 28th, 2020 - Background: Recently, using human colorectal and lung cancer, we showed that CD8+ T cells infiltrating tumor tissue (TILs) are not only specific for tumor antigens, but are also composed of CD8+ TILs specific for cancer unrelated epitopes – called bystander – such as HCMV, EBV or flu epitopes. We also showed that the surface marker CD39 can be useful for discriminating bystander (CD39−) from tu...

TCGA Kidney Cell Atlas: A differential gene expression database for the dissection of tumor-specific gene modules.
Saif Alimohamed

May 28th, 2020 - Background: The Cancer Genome Atlas project has become a leading source for data that has allowed the identification of a broad range of human cancer tumor types and subtypes and has revealed deep complexity with respect to the differentiation, or lack thereof, among human cancers. In particular, differential gene expression analyses have revealed a wealth of active oncogenic pathways, underlyi...

Cancer survivors with multiple chronic conditions: A rising challenge
Changchuan Jiang, MD, MPH

May 28th, 2020 - Background: Cancer survivors are disproportionally influenced by chronic/comorbid diseases, which were linked to more psychological distress, increased healthcare service use, higher medical costs, adverse clinical outcomes, and financial hardship in cancer survivors. However, the trend in chronic diseases remains unknown among cancer survivors. Methods: We conducted a population-based study us...

Lipocalin 2 – Devil or Angel? A pan cancer study.
Vijay Kumar Srinivasalu

May 28th, 2020 - Background: Lipocalin2 (LCN2, also known as neutrophil gelatinase-associated lipocalin), is a protein that in humans is encoded by the LCN2 gene. It’s abnormal expression serves critical roles in the EMT transition process, angiogenesis, cell migration and invasion in many cancers. We aim to study the expression of LCN2 in tumours with respect to normal and its association with survival in mult...

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: A machine learning approach.
Brian Dreyfus, MPH

May 28th, 2020 - Background: Many oncology treatments have been associated with cardiovascular (CV) adverse events. Cases of CV events, including myocarditis have been reported for PD-1 and PD-L1 therapies. We created a machine learning model to predict potential CV events in PD-(L)1 patients using the CancerLinQ database. Methods: A XGBoosted decision tree model was trained to predict a patient’s risk of serio...

Real-world usage and outcomes for patients treated with immune checkpoint inhibitors across multiple treatment indications in the Veterans Affairs system.
Jennifer La, PhD

May 28th, 2020 - Background: Increasingly broad patient groups are being treated with immune checkpoint inhibitors (ICIs) in clinical practice, but few studies have assessed their usage and outcomes in large, comprehensive real-world cohorts. In this study, we identified patients who received ICI therapy through April 2019 in the Veterans Affairs (VA) system. We described patient characteristics and assessed su...

Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data.
Prantesh Jain, MD

May 28th, 2020 - Background: Immune checkpoint inhibitors (ICIs) can cause unique, high-grade immune-related adverse events. Although rare, ICI related myocarditis has the highest fatality rate (~50%). Cardiovascular monitoring is not routinely performed in patients on ICI treatment, thus risk factors remain unknown. Characterizing rare but fatal cardiac toxicities requires integration of real-world data. Metho...

Checkpoint inhibitors related renal vasculitis and use of rituximab.
Omar Mamlouk

May 28th, 2020 - Background: As the percentage of cancer patients eligible for checkpoint inhibitor therapy (CPI) is increasing rapidly over the past couple years and approaching 45%, more cases of CPI related nephrotoxicity, including a rare subset with vasculitis, are reported. To learn more about the clinical presentation of CPI associated renal vasculitis, its mechanism, treatment options, and prognosis, we...

Thyroid dysfunction and immune checkpoint inhibitor outcomes.
Mitchell S. von Itzstein, MD

May 28th, 2020 - Background: Immune checkpoint inhibitors (ICI) frequently cause thyroid dysfunction. We performed a longitudinal analysis of thyroid function tests in a large, single-center cohort of patients with multiple cancer types receiving ICI. Methods: We performed a retrospective medical records review of consecutive patients treated with ICI from 1/1/2005 to 12/31/2018. We collected demographic and cl...

Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era.
Divya Ahuja Parikh, MD

May 28th, 2020 - Background: The treatment landscape for advanced renal cell carcinoma (RCC) has transformed in the past two years. Both Nivolumab plus Ipilimumab and Pembrolizumab plus Axitinib are approved regimens for first-line treatment of intermediate to poor-risk patients with advanced RCC. The choice between these immunotherapy-based combinations for first-line therapy is highly debated; no prior study ...